Product Information
ESOMEPRAZOLE MAG DR 20 MG CAP is a generic product labeled by Zydus Pharmaceuticals (USA) Inc., priced at $0.1446 per EA under NDC 68382044106. Its NADAC has been published 362 times since Oct 30, 2019.
FDA first approved this application on May 22, 2019. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
The High Outlier badge above means this manufacturer's average price in the esomeprazole magnesium market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
20 mg/1
Manufacturer
Zydus Pharmaceuticals (USA) Inc.NDC
68382044106
Classification
Generic
Dosage Form
CAPSULE, DELAYED RELEASE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
ESOMEPRAZOLE MAGNESIUM DIHYDRATEApproval Type
Generic (ANDA)
FDA Application
ANDA206296FDA Approved
5/22/2019
TE Code
AB
On Market Since
5/30/2019
Pharmacological Classes
Price Statistics
The NADAC for ESOMEPRAZOLE MAG DR 20 MG CAP has been published 362 times since Oct 30, 2019, and over the history we have for it it has declined 53.1%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.1446 per EA |
|---|---|
| All-time high | $0.3080 (Nov 13, 2019) |
| All-time low | $0.1307 (Nov 20, 2024) |
| 52-week high | $0.1690 |
| 52-week low | $0.1446 |
| Median price | $0.1951 |
| Average price | $0.2131 |
| Largest weekly change | +31.8% (Aug 21, 2024) |
| Weeks tracked | 362 |
| Tracking since | Oct 30, 2019 |
Generic Alternatives
The matcher finds 4 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Zydus Pharmaceuticals (USA) Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
esomeprazole magnesium market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Proton Pump Inhibitor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of ESOMEPRAZOLE MAG DR 20 MG CAP?
The current National Average Drug Acquisition Cost (NADAC) for ESOMEPRAZOLE MAG DR 20 MG CAP, manufactured by Zydus Pharmaceuticals (USA) Inc., is $0.1446 per EA (NDC 68382044106), effective Sep 30, 2026.
How has the price of ESOMEPRAZOLE MAG DR 20 MG CAP changed over time?
Over the history we have for it, the NADAC for ESOMEPRAZOLE MAG DR 20 MG CAP has declined 53.1%. It has been tracked across 362 weekly CMS publications since Oct 30, 2019.
What are the highest and lowest recorded NADAC prices for ESOMEPRAZOLE MAG DR 20 MG CAP?
Since Oct 30, 2019, the NADAC for ESOMEPRAZOLE MAG DR 20 MG CAP has ranged from a low of $0.1307 (Nov 20, 2024) to a high of $0.3080 (Nov 13, 2019), with a median of $0.1951 per EA.
Are there cheaper alternatives to ESOMEPRAZOLE MAG DR 20 MG CAP?
4 manufacturers publish a NADAC-priced product with the same active ingredient and strength as ESOMEPRAZOLE MAG DR 20 MG CAP in a comparable dosage form, but none are currently priced below it.
Who manufactures ESOMEPRAZOLE MAG DR 20 MG CAP?
ESOMEPRAZOLE MAG DR 20 MG CAP (NDC 68382044106) is labeled by Zydus Pharmaceuticals (USA) Inc., and CMS classifies it as a generic product.